Original language | English (US) |
---|---|
Pages (from-to) | 2437-2438 |
Number of pages | 2 |
Journal | Circulation |
Volume | 138 |
Issue number | 21 |
DOIs | |
State | Published - Nov 20 2018 |
Externally published | Yes |
Keywords
- calcium
- cardiovascular disease
- mortality
- pulmonary disease, chronic obstructive
- tomography, x-ray computed
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Circulation, Vol. 138, No. 21, 20.11.2018, p. 2437-2438.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Coronary Artery Calcium on Noncontrast Thoracic Computerized Tomography Scans and All-Cause Mortality
T2 - Genetic Epidemiology of COPD (COPDGene) Study
AU - Budoff, Matthew J.
AU - Lutz, Sharon M.
AU - Kinney, Gregory L.
AU - Young, Kendra A.
AU - Hokanson, John E.
AU - Barr, R. Graham
AU - Steiner, Robert
AU - Nath, Hrudaya
AU - Lopez-Garcia, Carmen
AU - Duca, Lindsey M.
AU - Rahmani, Sina
AU - Osawa, Kazuhiro
AU - Regan, Elizabeth A.
AU - Li, Dong
AU - Casaburi, Richard
N1 - Funding Information: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award No. K01HL125858 and No. K08 HL097029 (to Dr Lutz). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The coronary calcification data used in this manuscript are supported by the Tobacco-Related Disease Research Program Award No. 20XT-0014 (Principal Investigator: Dr Budoff). The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of As-traZeneca, Boehringer Ingelheim, Novartis, Pfizer, GlaxoSmithKline, Siemens, and Sunovion. The funding sources played no role in the design of the study or the decision to submit the manuscript for publication. Funding Information: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award No. K01HL125858 and No. K08 HL097029 (to Dr Lutz). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The coronary calcification data used in this manuscript are supported by the Tobacco-Related Disease Research Program Award No. 20XT-0014 (Principal Investigator: Dr Budoff). The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, GlaxoSmithKline, Siemens, and Sunovion. The funding sources played no role in the design of the study or the decision to submit the manuscript for publication.
PY - 2018/11/20
Y1 - 2018/11/20
KW - calcium
KW - cardiovascular disease
KW - mortality
KW - pulmonary disease, chronic obstructive
KW - tomography, x-ray computed
UR - http://www.scopus.com/inward/record.url?scp=85058910768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058910768&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.118.036835
DO - 10.1161/CIRCULATIONAHA.118.036835
M3 - Article
C2 - 30571584
AN - SCOPUS:85058910768
SN - 0009-7322
VL - 138
SP - 2437
EP - 2438
JO - Circulation
JF - Circulation
IS - 21
ER -